“…At present, the chemotherapeutic protocols for NSCLC mainly apply platinums as basic drugs combining with the third generation chemotherapeutic drugs such as paclitaxel, gemcitabine and vinorelbine, etc.. Multiple randomized clinical trials showed that the first-line treatment of double-drug protocol containing platinum had similar clinical effect on malignant tumors, for which the main differences were toxic characteristics and treatment costs (Sugiyama et al, 2011;Teramoto et al, 2012;Wang et al, 2012;He et al, 2013). Gemcitabine, a new-type of deoxycytidine analogue, can not only be used to inhibit ribonucleotide reductase to form hidden chains but also to improve cell apoptosis by rupturing the synthesis of DNA double chains.…”